// App-Quantinova.ai

4830 : Preclinical anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) + 5-FU + oxaliplatin in pancreatic cancer

Researchers

Presenter

  • Daniel F. Gaddy

Principal Investigators

  • Helen Lee

  • Nancy Paz

  • Shannon C. Leonard

  • Ashish Kalra

  • Ninfa L. Straubinger

  • Robert M. Straubinger

  • Bryan M. Gillard

  • Michael T. Moser

  • Daryl C. Drummond

  • Stephan G. Klinz

  • Bart S. Hendriks

  • Jonathan B. Fitzgerald

Medical Centers

  • Merrimack, Cambridge, MA

  • State University of New York at Buffalo, Buffalo, NY

  • Roswell Park Cancer Institute, Buffalo, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Metastatic pancreatic adenocarcinoma

  • Neutropenia

  • Solid malignancies

  • Microphthalmia, syndromic, 9

Biomarkers

  • N/A

Drug/Treatment

  • 5-fluorouracil + leucovorin

  • Irinotecan

  • Adrucil injection

  • Fluorouracil

  • Gemcitabine

  • Oxaliplatin

  • leucovorin

  • FOLFIRINOX

  • Irinotecan sucrosofate

  • SN38

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved